ライフサイエンスコーパス: atrial natriuretic

1 CNP and (Cys18)-atrial natriuretic factor (4-23) amide (cANF(4-23)) elic

2 19%), secreted more apoB, and expressed less atrial natriuretic factor (ANF) and brain natriuretic pe

3 5 haploinsufficiency also markedly decreased atrial natriuretic factor (ANF) and connexin 40 (cx40) t

4 function, its synergism with partners at the atrial natriuretic factor (ANF) and connexin-40 (Cx40) p

5 are markers of cardiac hypertrophy including atrial natriuretic factor (ANF) and myosin light chain-2

6 (GSK3beta) is critical for transcription of atrial natriuretic factor (ANF) by beta-adrenergic recep

7 induced increases in NADPH oxidase activity, atrial natriuretic factor (ANF) expression, and cardiac

8 IL-18 has also been shown to induce atrial natriuretic factor (ANF) gene expression in adult

9 The atrial natriuretic factor (ANF) gene is initially expres

10 otic expression screen for activators of the atrial natriuretic factor (ANF) gene, a cardiac-specific

11 its DNA binding sites in the promoter of the atrial natriuretic factor (ANF) gene, an in vivo target

12 Atrial natriuretic factor (ANF) is abundantly expressed

13 In contrast, while MnTMPyP inhibited basal atrial natriuretic factor (ANF) mRNA expression, the str

14 ed protein content, [3H] leucine uptake, and atrial natriuretic factor (ANF) promoter activity.

15 containing c-Jun and with the cardiomyocyte atrial natriuretic factor (anf) promoter and the cardiac

16 We report here that the atrial natriuretic factor (ANF) promoter is a target of

17 vation of cardiac gene promoters such as the atrial natriuretic factor (ANF) promoter.

18 ignificance of this interaction, we used the atrial natriuretic factor (ANF) promoter.

19 bx20, activates a cardiac-specific promoter (atrial natriuretic factor (ANF)) alone and synergistical

20 embryonic hearts expressed similar levels of atrial natriuretic factor (ANF), brain natriuretic pepti

21 Zic3(null/y) embryonic stem cells including atrial natriuretic factor (ANF), Nkx2.5 and Tbx5.

22 perated with c-Raf to increase expression of atrial natriuretic factor (ANF), whereas N17Rac1 inhibit

23 We found that atrial natriuretic factor (ANF), which is normally expre

24 ion of cardiac-specific genes, including the atrial natriuretic factor (ANF).

25 We investigated the potential of a C-type atrial natriuretic factor (C-ANF) to image developing pl

26 ently, we reported the (64)Cu-labeled C-type atrial natriuretic factor (CANF) fragment for detecting

27 mg/mm; p<0.001) and reduced LV expression of atrial natriuretic factor (p<0.05), alpha-skeletal muscl

28 nduced expression of two hypertrophic genes (atrial natriuretic factor [ANF] and c-myc) and also enha

29 spholamban restored the expression levels of atrial natriuretic factor and alpha-skeletal actin mRNA

30 n neonatal hearts, ventricular expression of atrial natriuretic factor and alpha-skeletal actin was m

31 ell area, protein content, and the mRNAs for atrial natriuretic factor and beta-MyHC.

32 ificantly increased heart/body weight ratio, atrial natriuretic factor and beta-myosin heavy chain mR

33 e cross-sectional areas, hypertrophy markers atrial natriuretic factor and beta-myosin heavy chain).

34 ition, two cardiac hypertrophy marker genes, atrial natriuretic factor and beta-myosin heavy chain, w

35 en synthesis and hypertrophy markers such as atrial natriuretic factor and beta-myosin heavy chain.

36 enuated expression of the trabecular markers atrial natriuretic factor and bone morphogenic protein 1

37 el pathways associated with up-regulation of atrial natriuretic factor and brain natriuretic peptide

38 ist-induced expression of the embryonic gene atrial natriuretic factor and enlargement of cardiomyocy

39 f the expression of various genes, including atrial natriuretic factor and Ifi204 (encoding p204).

40 trophy, increased expression of fetal genes (atrial natriuretic factor and skeletal alpha-actin), dec

41 rization ability inhibited the activation of atrial natriuretic factor by wild-type CSX/NKX2.5.

42 , overexpression of NF-kappaB itself induced atrial natriuretic factor expression and cardiomyocyte e

43 ment, sarcomeric organization, and increased atrial natriuretic factor expression in association with

44 P79 attenuated cardiomyocyte hypertrophy and atrial natriuretic factor expression in response to angi

45 Hypertrophy and atrial natriuretic factor expression induced by angioten

46 Atrial natriuretic factor expression was approximately 6

47 ha(1B)AR-induced hypertrophy and ventricular atrial natriuretic factor expression were significantly

48 ction, which induced myocyte hypertrophy and atrial natriuretic factor expression, protected against

49 ficant reduction in NF-kappaB activation and atrial natriuretic factor expression.

50 ed protein synthesis, cell surface area, and atrial natriuretic factor expression.

51 In contrast, secretion of atrial natriuretic factor from ventricular myocytes was

52 ocardin A transactivated the promoter of the atrial natriuretic factor gene through the serum respons

53 ssion of cardiac-specific promoters from the atrial natriuretic factor gene, the b-type natriuretic p

54 n, whereas it did not increase expression of atrial natriuretic factor gene.

55 ithin the proximal promoter -242 site of the atrial natriuretic factor gene.

56 ganization, increased cell size, and induced atrial natriuretic factor in cardiomyocytes plated on th

57 els of cardiac hypertrophy and expression of atrial natriuretic factor in Mekk1(-/-) animals, which s

58 s-sectional area, and hypertrophy-associated atrial natriuretic factor induction following pressure o

59 days) did not affect the trophic response or atrial natriuretic factor induction to pressure overload

60 c mass, myocyte size, hypertrophy-associated atrial natriuretic factor induction, and c-Jun N-termina

61 O mice shows a dramatic up-regulation of the atrial natriuretic factor message, a well-established bi

62 here were no significant changes in IGF-1 or atrial natriuretic factor mRNA levels in response to GH

63 in cell size, sarcomeric reorganization, and atrial natriuretic factor production were remarkably att

64 Serum increased atrial natriuretic factor promoter activity and cell siz

65 We tested atrial natriuretic factor promoter activity as a positiv

66 as co-transfected with SRF, but it repressed atrial natriuretic factor promoter activity, which was s

67 P-TF2dependent synergistic activation of the atrial natriuretic factor promoter by both GATA4 and the

68 educed the capability of SRF to activate the atrial natriuretic factor promoter that contains the ser

69 hat Tip60 and SRF cooperatively activate the atrial natriuretic factor promoter.

70 novel VEGF-B167 transgene controlled by the atrial natriuretic factor promoter.

71 onal responsiveness of ELK-1, GATA4, and the atrial natriuretic factor promoter.

72 that TBX5 activates the transcription of an atrial natriuretic factor reporter construct and this ef

73 ing adult heart, steady-state mRNA levels of atrial natriuretic factor were increased in both the fet

74 ed in the morphants including an increase in atrial natriuretic factor, a hallmark for cardiac hypert

75 we find that fluorescence from Topaz-tagged atrial natriuretic factor, a peptidergic vesicle pH indi

76 LV fibrosis, and expression of fetal genes (atrial natriuretic factor, alpha-skeletal muscle actin,

77 cardiac expression of HF marker genes (GRK2, atrial natriuretic factor, and beta-myosin heavy chain).

78 yosin heavy chain, cardiac troponin I and T, atrial natriuretic factor, and cardiac transcription fac

79 RNA expression of brain natriuretic peptide, atrial natriuretic factor, and renin were significantly

80 pregulation of hypertrophy markers including atrial natriuretic factor, beta-MHC, and GATA4; and acti

81 onic and contractile protein genes including atrial natriuretic factor, beta-myosin heavy chain, and

82 expression of the hypertrophic marker genes, atrial natriuretic factor, brain natriuretic peptide, an

83 pressed genes including cardiac alpha actin, atrial natriuretic factor, cardiac myosin heavy chain al

84 o well-known markers of cardiac hypertrophy (atrial natriuretic factor, CARP, and beta-myosin heavy c

85 n reaction, we measured transcript levels of atrial natriuretic factor, myosin heavy chain-alpha and

86 hy like: alpha- and beta-myosin heavy chain, atrial natriuretic factor, phospholamban, and sarcoplasm

87 However, in vivo imaging of a neuropeptide, atrial natriuretic factor, tagged with green fluorescent

88 Expression of fetal-type genes, such as atrial natriuretic factor, was also significantly lower

89 Atrial natriuretic factor, which signals via cGMP, also

90 ytosis were developed by expressing a prepro-atrial natriuretic factor-green fluorescent protein fusi

91 iferase gene expression but no activation of atrial natriuretic factor-luciferase gene expression.

92 accumulation, coincident with activation of atrial natriuretic factor-luciferase gene expression.

93 onomous accumulation of the endocytic tracer atrial natriuretic factor-red fluorescent protein at ear

94 Atrial natriuretic factor-VEGF-B167 expression was low i

95 osin heavy chain, myosin light chain 2v, and atrial natriuretic factor.

96 nduction of fetal genes such as betaMyHC and atrial natriuretic factor.

97 d expression of the hypertrophic marker gene atrial natriuretic factor.

98 ricles expressed beta-myosin heavy chain and atrial natriuretic factor.

99 y reduced ET-1- and PE-induced expression of atrial natriuretic factor.

100 e, sarcomeric organization, and induction of atrial natriuretic factor.

101 lmonary congestion and had reduced levels of atrial natriuretic factor.

102 r greater, P=0.001), had increased levels of atrial natriuretic peptide (7.3 versus 4.9 pmol/L, P=0.0

103 Atrial natriuretic peptide (ANP) acts acutely to reduce

104 The cardiac natriuretic peptides (NPs), atrial natriuretic peptide (ANP) and B-type natriuretic

105 the EGR1-regulated cardioprotective peptides atrial natriuretic peptide (ANP) and B-type natriuretic

106 Cardiomyocytes secrete atrial natriuretic peptide (ANP) and B-type natriuretic

107 of circulating cardiac natriuretic peptides, atrial natriuretic peptide (ANP) and B-type or brain nat

108 Atrial natriuretic peptide (ANP) and brain natriuretic p

109 ctivation of a fetal gene program, including atrial natriuretic peptide (ANP) and brain natriuretic p

110 at baseline, messenger ribonucleic acid for atrial natriuretic peptide (ANP) and brain natriuretic p

111 ct (IMCD) cells contributes to resistance to atrial natriuretic peptide (ANP) and the excessive sodiu

112 Subnanomolar concentrations of atrial natriuretic peptide (ANP) and type C natriuretic

113 he natriuretic signaling pathway in RPE with atrial natriuretic peptide (ANP) and with membrane-perme

114 Atrial natriuretic peptide (ANP) binding sites have been

115 After atrial natriuretic peptide (ANP) binding to NPRA, ligand

116 Atrial natriuretic peptide (ANP) binds guanylyl cyclase-

117 Atrial natriuretic peptide (ANP) binds guanylyl cyclase-

118 Corin is a recently discovered pro-atrial natriuretic peptide (ANP) convertase that is abun

119 cardiac serine protease that acts as the pro-atrial natriuretic peptide (ANP) convertase.

120 Circulating natriuretic peptides such as atrial natriuretic peptide (ANP) counterbalance the effe

121 ibited hypertrophy concurrent with increased atrial natriuretic peptide (ANP) expression that depende

122 mice, TAC resulted in a 15-fold increase in atrial natriuretic peptide (ANP) expression, a 55% incre

123 with Src, modulated basal and ET-stimulated atrial natriuretic peptide (ANP) gene promoter activity,

124 tudy was to investigate the impact of rs5065 atrial natriuretic peptide (ANP) gene variant on coronar

125 ciated with rs5068, a genetic variant of the atrial natriuretic peptide (ANP) gene.

126 mulated contractility, whereas 10 micromol/L atrial natriuretic peptide (ANP) had no effect.

127 Atrial natriuretic peptide (ANP) has a central role in r

128 The atrial natriuretic peptide (ANP) hormone is secreted by

129 The role of atrial natriuretic peptide (ANP) in regulating fetal car

130 e main receptor that mediates the effects of atrial natriuretic peptide (ANP) in the regulation of pl

131 assess the dynamics of nitric oxide (NO) and atrial natriuretic peptide (ANP) induced synthesis of in

132 Atrial natriuretic peptide (ANP) influences glucose home

133 Atrial natriuretic peptide (ANP) inhibited VPF signaling

134 Atrial natriuretic peptide (ANP) inhibits the proliferat

135 The cardiac hormone atrial natriuretic peptide (ANP) is a 28-amino acid (AA)

136 Atrial natriuretic peptide (ANP) is a cardiac hormone es

137 Atrial natriuretic peptide (ANP) is a cardiac hormone th

138 Atrial natriuretic peptide (ANP) is a hormone involved i

139 Atrial natriuretic peptide (ANP) is a hormone with diure

140 Atrial natriuretic peptide (ANP) is a hormone with numer

141 Atrial natriuretic peptide (ANP) is an endogenous peptid

142 of this study was to examine the effects of atrial natriuretic peptide (ANP) on cytosolic Ca2+ oscil

143 intravital microscopy to study the effect of atrial natriuretic peptide (ANP) on the extrasplenic mic

144 the major and possibly the only receptor for atrial natriuretic peptide (ANP) or B-type natriuretic p

145 Cyclic GMP (cGMP) made in response to atrial natriuretic peptide (ANP) or nitric oxide (NO) is

146 orskolin), we found that low doses of either atrial natriuretic peptide (ANP) or NO donors potentiate

147 Disruption of the atrial natriuretic peptide (ANP) receptor [guanylyl cycl

148 extracellular hormone binding domain of the atrial natriuretic peptide (ANP) receptor contains two p

149 The most studied member is the atrial natriuretic peptide (ANP) receptor, which is invo

150 y and guanylyl cyclase catalytic) domains of atrial natriuretic peptide (ANP) receptor-A (Npra) in po

151 st that oxytocin may mediate stretch-induced atrial natriuretic peptide (ANP) secretion.

152 ism for antiapoptotic signaling initiated by atrial natriuretic peptide (ANP) stimulation leading to

153 ier would attenuate the action of endogenous atrial natriuretic peptide (ANP) to increase vascular pe

154 Atrial natriuretic peptide (ANP) via its guanylyl cyclas

155 Circulating chimeric atrial natriuretic peptide (ANP) was detected in high co

156 ive partition analysis indicated that (125)I-atrial natriuretic peptide (ANP) was rapidly released in

157 12-amino acid extension to the C terminus of atrial natriuretic peptide (ANP) was recently geneticall

158 enzyme) is a cardiac protease that activates atrial natriuretic peptide (ANP), a cardiac hormone that

159 nd treat systemic hypertension by expressing atrial natriuretic peptide (ANP), a hormone able to decr

160 RP17 in cardiomyocytes enhances secretion of atrial natriuretic peptide (ANP), a regulator of blood p

161 al structures of the complexes of NPR-C with atrial natriuretic peptide (ANP), and with brain natriur

162 Concentrations of atrial natriuretic peptide (ANP), brain natriuretic pept

163 translated region of NPPA, the gene encoding atrial natriuretic peptide (ANP), is associated with blo

164 blood pressure and fluid homeostasis by the atrial natriuretic peptide (ANP), making PDE2-type enzym

165 The receptor for atrial natriuretic peptide (ANP), natriuretic peptide re

166 A cardiac hormone, atrial natriuretic peptide (ANP), plays a major role in

167 pro-atrial natriuretic peptide (pro-ANP) to atrial natriuretic peptide (ANP), suggesting that corin

168 ases in vascular permeability in response to atrial natriuretic peptide (ANP), which acts with the ki

169 GC) activity of the receptor protein in both atrial natriuretic peptide (ANP)-dependent and -independ

170 Nitric oxide (NO)- and atrial natriuretic peptide (ANP)-initiated cGMP signalin

171 exin A6 (Anxa6) to be a crucial regulator of atrial natriuretic peptide (ANP)-mediated counterhypertr

172 component of the intracellular modulation of atrial natriuretic peptide (ANP)-stimulated activation o

173 an endogenous receptor guanylate cyclase for atrial natriuretic peptide (ANP).

174 production of vasodilatory peptides, such as atrial natriuretic peptide (ANP).

175 ular leak can be prevented by treatment with atrial natriuretic peptide (ANP).

176 uanylate cyclase that acts as a receptor for atrial natriuretic peptide (ANP).

177 ATA4) that encodes a transcription factor of atrial natriuretic peptide (ANP).

178 udy tested the hypothesis that activation of atrial natriuretic peptide (ANP)/cGMP/protein kinase G s

179 Synthetic atrial natriuretic peptide (carperitide) and B-type natr

180 potential therapeutic applications of mutant atrial natriuretic peptide (mANP).

181 s the diagnostic utility of mid-regional pro-atrial natriuretic peptide (MR-proANP) for the diagnosis

182 enomedullin (MR-proADM), and midregional pro-atrial natriuretic peptide (MR-proANP) in a large prospe

183 sess the prognostic value of midregional pro-atrial natriuretic peptide (MR-proANP) in patients after

184 4 cardiovascular biomarkers, midregional pro-atrial natriuretic peptide (MR-proANP), midregional pro-

185 n AMI is the increased cardiac expression of atrial natriuretic peptide (NP) and B-type NP, with thei

186 th increased plasma levels of N-terminal pro-atrial natriuretic peptide (p = 0.002), after adjustment

187 in men, P<0.001 in women) and N-terminal pro-atrial natriuretic peptide (P<0.001 in men, P=0.001 in w

188 93 cells, we showed that corin converted pro-atrial natriuretic peptide (pro-ANP) to atrial natriuret

189 In cell-based studies, corin converted pro-atrial natriuretic peptide (pro-ANP) to mature ANP, sugg

190 C resulted in marked increases of myocardial atrial natriuretic peptide 4-hydroxy-2-nonenal (a marker

191 gical domains: neurohormonal (N-terminal pro-atrial natriuretic peptide [N-ANP], B-type natriuretic p

192 ohumoral factors, cytokines, endothelin, and atrial natriuretic peptide all may participate in HPA ax

193 Atrial natriuretic peptide also prevented stimulation of

194 Brain natriuretic peptide and atrial natriuretic peptide also released norepinephrine

195 ion of the fetal gene program (ie, increased atrial natriuretic peptide and alpha skeletal actin gene

196 for age and clinical covariates, N-terminal atrial natriuretic peptide and B-type natriuretic peptid

197 In men, N-terminal atrial natriuretic peptide and B-type natriuretic peptid

198 rdiovascular regulator that is stimulated by atrial natriuretic peptide and B-type natriuretic peptid

199 ions of natriuretic peptides (N-terminal pro-atrial natriuretic peptide and B-type natriuretic peptid

200 s less hypotensive than the cardiac peptides atrial natriuretic peptide and B-type natriuretic peptid

201 eased expression of cardiac embryonic genes (atrial natriuretic peptide and beta-myosin heavy chain)

202 logical properties with the cardiac hormones atrial natriuretic peptide and brain natriuretic peptide

203 NPR)-A is the primary signaling receptor for atrial natriuretic peptide and brain natriuretic peptide

204 In competition binding experiments, atrial natriuretic peptide and brain type natriuretic pe

205 The binding of atrial natriuretic peptide and C-type natriuretic peptid

206 Other substrates of IDE such as atrial natriuretic peptide and glucagon also competitive

207 ated the TAC-induced increases of myocardial atrial natriuretic peptide and the oxidative stress mark

208 Moreover, while levels of mRNA encoding atrial natriuretic peptide are reduced in E17.5 GR(-/-)

209 contribute) is the key process through which atrial natriuretic peptide attenuates elevations in cyto

210 ales, cardiac expression of the precursor of atrial natriuretic peptide B and of adrenomedullin also

211 neuropeptides gastrin-releasing peptide and atrial natriuretic peptide B in the spinal cord.

212 The cardiac serine protease corin is the pro-atrial natriuretic peptide convertase.

213 We show that atrial natriuretic peptide does not modulate the release

214 ressed in mice revealed that this unexpected atrial natriuretic peptide effect is brought about by sp

215 iogenesis, increased Akt activity, decreased atrial natriuretic peptide gene expression, and maintena

216 ntricular myocytes, with increased secretory atrial natriuretic peptide granules and degenerative mye

217 ns, the most intriguing have been the use of atrial natriuretic peptide in patients with nonoliguric

218 mm(2), P < 0.01) and marker gene expression (atrial natriuretic peptide increased by 409 +/- 32%, and

219 Finally, we revealed that atrial natriuretic peptide increased phosphorylation of

220 lls, both the NO donor S-nitrosocysteine and atrial natriuretic peptide induced SSG1 phosphorylation,

221 Atrial natriuretic peptide is a circulating hormone that

222 Midregional pro-atrial natriuretic peptide is a newly described stable f

223 Midregional pro-atrial natriuretic peptide is a powerful predictor of ad

224 rdiomyocytes expression of the stress-marker atrial natriuretic peptide is suppressed by EMD 57033.

225 The reductions in vasopressin and atrial natriuretic peptide levels after captopril did no

226 Midregional pro-atrial natriuretic peptide may represent a clinically us

227 ulate the reduced fat oxidation and elevated atrial natriuretic peptide message of cardiac hypertroph

228 of this study was to examine the effects of atrial natriuretic peptide on potentially harmful elevat

229 one (NT-pro-BNP), and N-terminal fragment of atrial natriuretic peptide pro-hormone (NT-pro-ANP) leve

230 e hypertension, and corin activation and pro-atrial natriuretic peptide processing activity were unde

231 ented corin activation and inhibited its pro-atrial natriuretic peptide processing activity.

232 hese pathways, related to the stimulation of atrial natriuretic peptide production and secretion.

233 iously undiscovered, mechanism through which atrial natriuretic peptide protects rat hepatocytes, and

234 two categorically different models (lack of atrial natriuretic peptide receptor A; overexpression of

235 The atrial natriuretic peptide secreted by atrial myocytes i

236 It converts pro-atrial natriuretic peptide to atrial natriuretic peptide

237 -type natriuretic peptide and N-terminal pro-atrial natriuretic peptide to the risk of death from any

238 e was 24% lower (P<0.001) and N-terminal pro-atrial natriuretic peptide was 16% lower (P<0.001); in w

239 e was 29% lower (P<0.001) and N-terminal pro-atrial natriuretic peptide was 18% lower (P<0.001).

240 Atrial natriuretic peptide was found to be up-regulated

241 ncluded vasoactive peptides; the vasodilator atrial natriuretic peptide was induced by CSD, while the

242 - or 12-week-old animals, and the PCH marker atrial natriuretic peptide was not different in young ve

243 s, extracellular matrix (ECM), integrin, and atrial natriuretic peptide were assessed.

244 -type natriuretic peptide and N-terminal pro-atrial natriuretic peptide with metabolic risk factors,

245 estry, and identified associations of plasma atrial natriuretic peptide with rs5068 (P = 8 x 10(-70))

246 he expression of known hypertrophic markers (atrial natriuretic peptide) and transcription factor act

247 etic peptides (C-type natriuretic peptide >> atrial natriuretic peptide) and, to a much smaller exten

248 ells expressed middle neurofilament (but not atrial natriuretic peptide) mRNA and protein.

249 gic hypertrophy (beta-myosin heavy chain and atrial natriuretic peptide) was measured with a quantita

250 n-1, CT-pro-arginine vasopressin, and MR-pro-atrial natriuretic peptide), alone or as a panel, could

251 ic* and pulmonary* vascular resistances, and atrial natriuretic peptide*.

252 t converts pro-atrial natriuretic peptide to atrial natriuretic peptide, a cardiac hormone that regul

253 n plasma adrenomedullin, with higher urinary atrial natriuretic peptide, adrenomedullin, and cGMP exc

254 , B-type natriuretic peptide, N-terminal pro-atrial natriuretic peptide, aldosterone, renin, fibrinog

255 ) of cardiac-specific genes (Nkx2.5, GATA-4, atrial natriuretic peptide, alpha- and beta-myosin heavy

256 leation, molecular up-regulation of released atrial natriuretic peptide, altered expression of classi

257 nosine reduced cell area, protein synthesis, atrial natriuretic peptide, and 3'-nitrotyrosine.

258 ion, LVEF, serum ACE, plasma angiotensin II, atrial natriuretic peptide, and brain natriuretic peptid

259 m salt (DEA/NO) or the natriuretic peptides, atrial natriuretic peptide, and C-type natriuretic pepti

260 itivities of their cGMP responses to DEA/NO, atrial natriuretic peptide, and C-type natriuretic pepti

261 rations for histology, middle neurofilament, atrial natriuretic peptide, and connexin (Cx) 43 reveale

262 agents at this time appear to be adenosine, atrial natriuretic peptide, and cyclosporine, with other

263 ulate whereas somatostatin, cholecystokinin, atrial natriuretic peptide, and nitric oxide inhibit aci

264 ene-related peptide, adrenomedullin, amylin, atrial natriuretic peptide, and pituitary adenylate cycl

265 mic arteries with substance P, epoprostenol, atrial natriuretic peptide, and relaxin (concentration r

266 for reduced fat oxidation to affect cardiac atrial natriuretic peptide, and thus, induce adipose lip

267 assessed the relations of plasma N-terminal atrial natriuretic peptide, B-type natriuretic peptide,

268 l, carbonyls), hypertrophic gene expression (atrial natriuretic peptide, B-type natriuretic peptide,

269 tricular expressions of the genes coding for atrial natriuretic peptide, beta myosin heavy chain, med

270 g expression of the hypertrophy gene markers atrial natriuretic peptide, brain natriuretic peptide, b

271 Phase 2 began with de Bold's discovery of atrial natriuretic peptide, followed by isolation of the

272 rprisingly, L-CPT1 hearts contained elevated atrial natriuretic peptide, indicating induction of hype

273 odilatin, the renally synthesized isoform of atrial natriuretic peptide, may improve pulmonary conges

274 action of numerous other regulators such as atrial natriuretic peptide, neurotensin, and orexin B ar

275 n effect further enhanced in the presence of atrial natriuretic peptide, NO, and treprostinil.

276 gregate (amylin, ACTH, LHRH, angiotensin II, atrial natriuretic peptide, somatostatin, oxytocin, neur

277 3T3 cells was increased by prior exposure to atrial natriuretic peptide, suggesting that hormone bind

278 We show that atrial natriuretic peptide, through protein kinase G, at

279 the approximately 180-kDa fragment activated atrial natriuretic peptide, whereas the approximately 16

280 However, the atrial natriuretic peptide, which is induced during left

281 mplants to produce sufficient amounts of the atrial natriuretic peptide, which reduced the blood pres

282 lective PDE2 inhibitor BAY 60-7550 augmented atrial natriuretic peptide- and treprostinil-evoked pulm

283 Corin (also known as atrial natriuretic peptide-converting enzyme) is a cardi

284 This report implicates perturbation of the atrial natriuretic peptide-cyclic guanosine monophosphat

285 g both the renin-angiotensin-aldosterone and atrial natriuretic peptide-degrading systems simultaneou

286 f rats with RO-25-6760 for 7 d increased the atrial natriuretic peptide-dependent excretion of sodium

287 PDE5 inhibition did not alter atrial natriuretic peptide-stimulated cGMP in the restin

288 c protease responsible for the activation of atrial natriuretic peptide.

289 described stable fragment of N-terminal pro-atrial natriuretic peptide.

290 tion of the cardiac-derived peptide hormone, atrial natriuretic peptide.

291 lar results were obtained for N-terminal pro-atrial natriuretic peptide.

292 sue weight assessment and gene expression of atrial natriuretic peptide.

293 All patients showed low serum levels of atrial natriuretic peptide.

294 re healthy and demonstrated normal levels of atrial natriuretic peptide.

295 r function, and severely decreased levels of atrial natriuretic peptide.

296 cant even after adjusting for N-terminal pro-atrial natriuretic peptide.

297 ous frameshift mutation in the gene encoding atrial natriuretic peptide.

298 or-stimulated cardiomyocyte contractility by atrial natriuretic peptide/cGMP signaling in early cardi

299 lamines, renin, aldosterone, angiotensin and atrial natriuretic peptides (ANP, N-ANP and BNP) were me

300 The NPPA gene codes for the precursor of atrial natriuretic polypeptide, suggesting that NPPA may